Citations

Clear

4610 citation(s) found for "Hu, Brian".

PART characterization using MK‐6240 and Flortaucipir
Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Rocha, Andreia, Bellaver, Bruna, Oliveira, Markley Silva , Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Soares, Carolina , Ruppert, Emma Patrice , Ferreira, Pâmela C.L. , Madeiros, Marina Scop, Rocha, Andreia, Rodrigues, Matheus Scarpatto , Bellaver, Bruna , Povala, Guilherme , Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106723 Get It

Abstract Background Older adults with brain tau pathology but no evident amyloid‐beta (A) pathology can be referred to as primary age‐related tauopathy (PART). However, in vivo characterization of PART using biomarkers remains unclear, varying based on the method used to define tau pathology (e.g. different tau‐PET tracers). Here, we conducted a head‐to‐head characterization of PART using two different tau‐PET tracers. Method We studied 433 individuals from the HEAD cohort (244 CU, 138 MCI, and 51 with dementia). Participants underwent clinical assessments, MRI, A‐PET, both MK‐6240 and Flortaucipir scans, and a subset with plasma biomarkers ( n = 332). A‐PET positivity was defined as Centiloid>24. Tau‐positivity(T) was determined by MK‐6240 and Flortaucipir SUVR values exceeding the mean+2SD in at least one Braak region anchored in CU A‐ individuals followed by visual confirmation in A‐/T+ cases. Concordance across biomarkers was assessed among PART (A‐/T+), A‐/T‐ and A+/T+ groups. Plasma GFAP, p ‐tau217, NFL levels, and Centiloids were compared across A/T groups using linear regression. Result We found a total of 25 (5.8 %) cases classified as A‐/T+ defined by at least one tau tracer (74±6.3 years, 52% females, 17 CU, 3 MCI, 5 with dementia). Detection of A‐/T+ cases varied by tracer: MK‐6240( n = 20), Flortaucipir( n = 16) (Figure 1A). Among A‐/T+ individuals, MK‐6240 identified 13 CU, 4 MCI, and 3 dementia cases, while Flortaucipir identified 11 CU, 3 MCI, and 2 dementia cases(Figure 1B). Concordance between MK‐6240 and Flortaucipir in A‐/T+ cases was low ( n = 11, 44%)(Figure 1C). A‐/T+ individuals showed no significant biomarker differences from A‐/T‐ but had lower biomarker levels than A+/T+: Centiloids (MK‐6240: T=15.08, p <0.001; Flortaucipir: T=14.36, p <0.001), GFAP (MK‐6240: T=5.04, p < 0.01; Flortaucipir: T=2.92, p <0.001), p ‐tau217 (MK‐6240: T=7.77, p <0.001; Flortaucipir: T=6.34, p <0.001), except for NFL (MK‐6240: T=1.35, p = 0.18; Flortaucipir: T=1.14, p = 0.25)(Figure 2). Representative A and tau biomarker cases (Figure 3A), along with discordant cases classified as T+ by only one tracer (Figure 3B), are illustrated. Conclusion Our preliminary analysis revealed a higher prevalence of A‐/T+ cases with MK‐6240 than Flortaucipir, low concordance between tracers and consistently lower biomarker levels in A‐/T+ compared to A+/T+. Larger studies and longitudinal analyses are necessary to ascertain the pathological trajectories of A‐/T+ individuals with varying tau biomarker profiles.
Head‐to‐Head evaluation of plasma p ‐tau217 associations with MK6240, Flortaucipir, PI2620, and RO948 tau PET tracers
Ferreira, Pamela C.L., Chan, Tevy , Bellaver, Bruna, Povala, Guilherme, Soares, Carolina, Felix, Cynthia, Rocha, Andreia, Madeiros, Marina Scop, Amaral, Lívia , Cehula, Juli, Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Ferreira, Pâmela C.L. , Bellaver, Bruna , Povala, Guilherme , Bauer‐Negrini, Guilherme , Ruppert, Emma Patrice , Soares, Carolina , Felix, Cynthia , Rocha, Andreia, Madeiros, Marina Scop, Cehula, Juli, Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106115 Get It

Abstract Background Tau phosphorylation and aggregation are hallmark features of Alzheimer's disease pathology(AD). Previous studies have shown that plasma phosphorylated tau( p ‐tau) at threonine 217 can detect AD‐related tau tangle pathology. However, the head‐to‐head association between p ‐tau217 and different tau PET tracers remains unexplored. Here, we conducted a head‐to‐head comparison of the association between plasma p ‐tau217 and four distinct tau PET tracers[MK6240, Flortaucipir(FTP), PI2620, RO948]. Method We studied 338 individuals across the AD continuum from the HEAD study[190 cognitively unimpaired elderly(CU), 109 with mild cognitive impairment(MCI), and 39 with dementia] with available FTP, MK6240, and plasma p ‐tau217 measured by ALZpath assay. A subset of 64 individuals(28 CU, 25 MCI, and 11 dementia) also had PI2620 and RO948, and p ‐tau217 measured by Lumipulse. The strength of the association was determined using t‐value maps from regression models testing the association between each tau PET tracer and plasma p ‐tau217, and the extent was measured by the percentage of significant voxels(t‐value>3.2). R‐square metric was used to determine how much of the variance in tau PET tracer estimates was explained by plasma p ‐tau217 concentrations. Associations between p ‐tau217 with tau PET were evaluated using the Spearman test. Result We found that in CU, both the extent and magnitude of the association with plasma p ‐tau217 were higher for MK6240 compared to FTP (Figure 1A‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240 than in FTP (Figure 1E‐F). In CI, the extent and magnitude of the association were similar for MK6240 and FTP. Additionally, plasma p ‐tau217 explained a similar proportion of the variance in MK6240 and FTP. Using the subset of individuals who had all tau tracers, MK6240 showed a slightly higher extent of association with p ‐tau217, followed by FTP, PI2620, and RO948 (Figure 2A‐B). The magnitude of association was stronger for MK6240, followed by PI2620, RO948, and FTP (Figure 2C‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240, followed by FTP, RO948, and PI2620 (Figure 2E‐F). We compared the associations between different p ‐tau217 assays, and both assays presented similar associations with all tau PET tracers (Figure 3). Conclusion In summary, our results indicate that the four tau PET tracers exhibit robust associations with plasma p ‐tau217 in similar topographical regions.
Evaluation discrepancy between [ 18 F]MK‐6240 and [ 18 F]AV‐1451 tau‐PET using tau‐PET overlap index
Lim, Seokbeen , Brunn, Jessica L., Soleimani‐Meigooni, David N., Oh, Hwamee, Fortea, Juan M., Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Povala, Guilherme, Pascoal, Tharick A, Lowe, VJ, Min, Hoon-Ki Paul , Soleimani‐Meigooni, David N. , Oh, Hwamee , Fortea, Juan , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Lussier, Firoza Zubeida , Povala, Guilherme , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106145 Get It

Abstract Background The overlap index (OI), previously introduced by Lee et al. (2022), has proven to be a reliable method for detecting tau accumulation via tau‐PET imaging with flortaucipir ([ 18 F]AV‐1451). This technique identifies voxel‐wise increases in standardized uptake value ratio (SUVr) across serial scans. However, the relationship between tau‐PET measurements obtained with [ 18 F]MK‐6240 and [ 18 F]AV‐1451 using the OI remains unclear. This study aims to investigate the relationship between [ 18 F]MK‐6240 and [ 18 F]AV‐1451 tau‐PET using the tau‐PET OI. Method The study included 27 participants from the HEAD project, all of whom underwent two serial tau‐PET scans (each [ 18 F]MK‐6240 and [ 18 F]AV‐1451) along with 3T T1‐weighted MRI, acquired within an average interval of 18 months. SUVr maps for each tau‐PET tracer were normalized to the cerebellar crus grey matter, and MR images were co‐registered to the MCALT T1 template. Tau‐PET images were spatially resampled to the template space, and OI was computed within a predefined META‐ROI using an intensity threshold of 1.3 and a cutoff of 0.5. Clusters containing fewer than 20 contiguous voxels were excluded from analysis. The META‐ROI SUVr was calculated as the average SUVr across the selected region's SUVr. Additionally, a visual comparison was performed to assess the spatial overlap of OI‐identified voxels between the two tau‐PET tracers. Result OI values within the META‐ROI exhibited a broad distribution between [ 18 F]MK‐6240 and [ 18 F]AV‐1451 tau‐PET, particularly in cognitively unimpaired (CU) and younger individuals (Figure 1A). Unlike the OI distribution, the relationship between META‐ROI SUVr values of both tracers followed an exponential trend (Figure 1B). Visual inspection revealed that OI‐detected voxels in [ 18 F]MK‐6240 tau‐PET were frequently localized to the meninges, an established site of off‐target binding, which was not observed in [ 18 F]AV‐1451 tau‐PET (Figure 2). Conclusion The association between [ 18 F]MK‐6240 and [ 18 F]AV‐1451 tau‐PET, as assessed using the OI, exhibited considerable variability in CU and younger participants. Additionally, the presence of overlapping voxels in the meninges in [ 18 F]MK‐6240 tau‐PET highlights the need to account for and potentially exclude off‐target binding effects in these populations. The influence of meningeal signal and other off‐target binding on the OI in the temporal META‐ROI needs to be further evaluated.
Aβ‐dependent trajectories of Braak stages for MK6240 and Flortaucipir tau PET
Bellaver, Bruna, Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Rocha, Andreia, Masdeu, Joseph C. , Tudorascu, DL, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Rocha, Andréia Silva da , Pascual, Belen , Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rocha, Andreia, Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107040 Get It

Abstract Background Tau accumulation in the brain is postulated to follow a hierarchical pattern, known as Braak staging, originally defined in postmortem brains. PET‐based Braak stages have since been proposed, however, tau PET tracers exhibit distinct binding characteristics that might influence the detectable trajectories of tau accumulation and its relationship with other biomarkers across the AD continuum. In a head‐to‐head study, we investigated the emergence of tau positivity in each Braak region, along with plasma p ‐tau217 and GFAP, as a function of Aβ PET deposition. Method We evaluated 352 individuals from the HEAD study (205 cognitively unimpaired and 147 cognitively impaired) with head‐to‐head Aβ PET, MK6240 and Flortaucipir tau PET, and plasma p ‐tau217 (ALZpath) and GFAP (Quanterix) measures. Tau PET Braak regions, plasma p ‐tau217 and GFAP trajectories were modeled as functions of Aβ burden (Centiloid scale) using the Lowess method. Biomarkers were z‐scored anchored on young individuals ( n = 19, <28 years old). Positivity for plasma biomarkers and for each Braak region was determined when values surpassed 2.5 z‐score from the mean. Result Among the tested markers, plasma GFAP was the earliest to show abnormality as a function of Centiloid, occurring at 11 Centiloids. For MK6240, Braak I was the first regions to became positive (at 22 Centiloids), followed by Braak II (at 32 Centiloids), Braak IV (at 42 Centiloids), Braak III (at 52 Centiloids), Braak V (at 70 Centiloids) and Braak VI (at 123 Centiloid; Figure 1A). For Flortaucipir the first region to became positive was Braak IV (at 50 Centiloids), followed by Braak I and II (both at 56 Centiloids), Braak III (at 85 Centiloids) and Braak V (at 92 Centiloids). Braak VI region did not reach the threshold for positivity in our population (Figure 1B). Plasma p ‐tau217 reached the positivity threshold at 38 Centiloids. Conclusion MK6240 follows a Braak stage‐like pattern of abnormality as a function of Aβ burden, whereas for Flortaucipir, Braak IV is the first region to became abnormal. MK6240 becomes abnormal at lower Aβ burden levels compared to plasma p ‐tau217 and Flortaucipir but after plasma GFAP. Our findings suggest that MK6240 might detect tau pathology in earlier disease stages than Flortaucipir.
Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab
Joseph‐Mathurin, Nelly, Chen, Charles D., Hobbs, Diana A, Flores, Shaney, Scott, Jalen, Anand, Sanjana, Franklin, Erin E., Lu, Ruijin , Gordon, Brian A., Jack, Clifford R., Cruchaga, Carlos, Hassenstab, Jason J., Ibanez, Laura, Li, Yan, Wang, Guoqiao, Renton, Alan E., Xiong, Chengjie, Atri, Alireza, Snider, B. Joy, Llibre‐Guerra, Jorge J., Clifford, David B., McDade, DO Eric, Bateman, Randall J., Wang, Qing, Perrin, Richard J., Benzinger, Tammie L.S., team, DIAN‐TU study, Joseph‐Mathurin, Nelly , Jiang, Meng, Flores, Shaney , Franklin, Erin , Gordon, Brian A. , Jack, Clifford R. , Cruchaga, Carlos , Hassenstab, Jason , Ibanez, Laura , Li, Yan, Wang, Guoqiao , Renton, Alan , Xiong, Chengjie , Atri, Alireza , Snider, B. Joy, Llibre‐Guerra, Jorge J. , Clifford, David B. , McDade, Eric , Bateman, Randall J. , Wang, Qing , Perrin, Richard J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107139 Get It

Abstract Background Amyloid related imaging abnormality edema (ARIA‐E) occurs in about 19% of individuals with autosomal dominant Alzheimer disease (ADAD) treated with an anti‐amyloid‐b monoclonal antibody (Salloway et al., 2021). In a previously reported case, ARIA‐E appeared to colocalize with decreases in PiB‐PET uptake (Joseph‐Mathurin, Llibre‐Guerra, et al, 2022), suggesting an association between amyloid‐b (Aβ) removal and ARIA‐E. Here, we compare longitudinal neuroimaging and corresponding neuropathology in an ADAD individual treated with gantenerumab, who experienced multiple ARIA‐E episodes as sulcal effusions that resolved by the end of the four‐year trial. Methods PiB‐PET and MRI were collected pre‐ and post‐randomization (2 and 4 years). The participant consented to brain donation, which was received a year after trial completion. Four tissue samples were taken from the location of the ARIA‐E in the parieto‐occipital left hemibrain as identified by MRI (one block contained the sulcus affected by ARIA‐E; the rest of the coronal section was captured in the remaining three blocks). Area fractions (AFs) of Aβ (10D5 immunohistochemistry (IHC)), tauopathy (PHF1), microglia (Iba1), and astrocytes (GFAP) in one sulcal region of interest (ROI) from each block and PiB‐PET SUVRs of corresponding ROIs were extracted ( n = 4, Figure 1). Additionally, we included PiB‐PET SUVRs corresponding to ARIA‐E findings observed in the right hemisphere at baseline, two‐year, and four‐year visits ( n = 6). Results Overall PiB‐PET uptake increased during the first two years (before ARIA‐E) and decreased during the last two years (including ARIA‐E episodes) (0.03±0.05 vs. ‐0.04±0.04 SUVR/year, p ‐value=0.01, Figure 2). The decrease seemed more pronounced in ARIA‐E ROIs versus normal‐appearing sulcus ROIs (‐0.05±0.04 vs. ‐0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p ‐value=0.07). The ARIA‐E ROI had an Aβ AF of 0.009 while normal‐appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal‐appearing sulcus ROIs, suggesting an Aβ‐specific effect, although unexamined markers may play a role. Conclusions Our preliminary findings indicated that ARIA‐E is associated with longitudinal PiB‐PET decrease and Aβ AF, supporting the link between ARIA‐E, changes in PiB‐PET, and local Aβ removal observed at autopsy. Funding : K01AG080123; U01AG042791; R01AG046179; R01AG053267
Tau exacerbates the development of motor disturbances but has no effect on the development of irritability across the Braak stages – The HEAD Study
Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Soares, Carolina, Medeiros, Marina Scop , Ferrari‐Souza, João Pedro, Bellaver, Bruna, Zalzale, Hussein, Zimmer, Eduardo R., Tudorascu, DL, Pascual, Belen, Gordon, Brian A., Lowe, VJ, Oh, Hwamee, Soleimani‐Meigooni, David N., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Pascual, Belen , Aguzzoli, Cristiano Schaffer , Povala, Guilherme , Ferreira, Pâmela C.L. , Lussier, Firoza Zubeida , Bauer‐Negrini, Guilherme , Soares, Carolina , Ferrari‐Souza, João Pedro , Bellaver, Bruna , Rohden, Francieli , Leffa, Douglas Teixeira , Schilling, Lucas Porcello , Zimmer, Eduardo Rigon , Tudorascu, Dana , Gordon, Brian A. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105322 Get It

Abstract Background Previous studies demonstrated an association between tau pathology and the development of neuropsychiatric symptoms (NPS) in individuals with Alzheimer's disease (AD). However, the extent to which tau influences each specific NPS domain remains unclear. Here, we aim to investigate the association of tau and each NPS domain in the AD continuum. We hypothesized that tau plays a comparatively greater effect on the emergence of hyperactive and psychotic symptoms compared to other NPS domains. Method We assessed 385 individuals (216 cognitively unimpaired (CU), 128 MCI, and 41 AD dementia) from the HEAD study who underwent clinical assessments with the Neuropsychiatry Inventory Questionnaire (NPI‐Q) and had positron emission tomography (PET) for amyloid‐β (Aβ) ([ 18 F]AZD4694 or [ 11 C]PiB), and tau tangles ([ 18 F]MK6240) at the same visit. Tau SUVR values were tailored with a mask from Braak stages I‐VI, using the inferior cerebellar gray matter as a reference region. All individuals with dementia had a positive Aß‐PET. Voxel‐wise and Tobit censored regression tested the association between NPS domains and biomarkers accounting for age, sex, cognitive status, and study site. We used censored regression models to account for skewed data alongside a leave‐one‐out (loo) approach to identify which NPS domains most contributed to results. Result CI individuals had significantly higher NPI‐Q scores and Tau PET SUVR than CU (Figure 1A, 1B). NPI‐Q score was significantly associated with tau‐PET predominantly in fronto‐parietal regions. Removing irritability from the models strengthened this association (Figures 2A‐C). Regression loo models revealed that motor disturbances contributed most to the association between NPS and tau‐PET across all Braak stages. Notably, irritability had a negative effect on the association in all Braak stages, suggesting that tau does not play a role in the development of irritability and is highly associated with motor disturbances (Figure 3). Conclusion Our study suggests that tau contributes to the development of motor disturbances but has no effect on the development of irritability across the AD continuum. These findings provide additional rationale for the development of new therapeutics aiming to mitigate motor disturbances and irritability in AD patients.
Head‐to‐head in vivo Braak staging with MK6240 and Flortaucipir
Rocha, Andreia, Bellaver, Bruna, Madeiros, Marina Scop, Soares, Carolina, Ferreira, Pamela C.L., Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C. , Tudorascu, DL, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Medeiros, Marina Scop , Pascual, Belen , Rocha, Andreia, Bellaver, Bruna , Ruppert, Emma Patrice , Madeiros, Marina Scop, Soares, Carolina , Ferreira, Pâmela C.L. , Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rodrigues, Matheus Scarpatto , Masdeu, Joseph C , Tudorascu, Dana , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107534 Get It

Abstract Background In vivo Braak staging stratifies patients across the AD spectrum and has the potential to harmonize tau PET tracer staging. This study aims to compare and test harmonization procedures for Braak staging individuals using MK6240 and Flortaucipir tau PET tracers. Methods We assessed 437 participants across the AD spectrum (245 cognitively unimpaired (CU) and 192 cognitively impaired; mean age 68.5 ± 8.6) using head‐to‐head MK6240 and Flortaucipir scans. We computed SUVRs in Braak regions of interest (ROIs) and assessed four cut‐off methods for Braak positivity: (a) mean + 2.5 SD of young controls (age <28 years), (b) mean + 2.5 SD of elderly CU Aβ−, (c) Gaussian mixture modeling (GMM), and (d) the Youden index. Braak stages were assigned using seven (0 to VI) or four (0, I–II, III–IV, V–VI) categories. We evaluated inter‐ and intra‐tracer concordance (intra‐tracer, i.e., whether it follows the sequential Braak pattern). Results The intra‐tracer seven‐class Braak staging concordance ranged from 63% to 94%. With the highest intra‐tracer Braak concordance being achieved when using GMM cutoffs: 94% (MK6240) and 89% (Flortaucipir; Figure 1). Inter‐tracer agreement concordance ranged from 56% to 76%. The highest concordance emerged from the CU Elderly Aβ– cutoff optimizing the Braak II region for spill‐off (Figure 2). Using the Braak staging simplified version improved intra‐tracer concordance in both tracers (MK6240as well as inter‐tracer agreement (86.5%). Most inter‐tracer discrepancies were observed at Braak stages II–IV. Despite showing staging discordances, the distribution of cognitive status across the Braak stages is similar for both tracers (Figure 3). Conclusion These preliminary findings reveal some discrepancies in Braak staging when comparing MK6240 and Flortaucipir. Our results also suggest that adjustments in cutoffs and regions of interest can partially mitigate both inter‐ and intra‐tracer divergences. Finally, our analysis suggests robust concordance after adjustment and using 4 classes (0, I‐II, III‐IV, V‐VI).
Lost fractures: prevalence and risk factors for missed costosternal and costal cartilage fractures among patients with radiologic chest wall injury
Forrester, Joseph D , Chaar, Mohamad Abou, Barnes, Andrew T, Bauman, Zachary M, Bendjemil, Samy, Betts, Nizama N, Christie, Benjamin, Dasari, Raaga, WB, Devoe, Earley, Michelle J., Faliks, Bradley , Johns, Tracy J, Johnson, Connie, Junker, Michelle S., Kim, B. D., King, Jonathan, Knight, Ariel W. , Schweibinz, Alexis, Stephens, Daniel, Stuever, Mary, Wang, Simeng , Forrester, Joseph D. , Chaar, Mohamad K. Abou , Stephens, Daniel , Abou Chaar, Mohamad , Kim, Brian D. , King, Jonathan M , Knight, Ariel Whitney , Bauman, Zachary Mitchel , DeVoe, William B. , Johns, Tracy J. , Stuever, Mary, Stephens, Daniel

Mayo Clinic

Trauma Surgery & Acute Care Open | January 9, 2026 | Volume: 11 | Issue: 1 | Pages: e002020

10.1136/tsaco-2025-002020 | PMID 41561394 Get It

Background Costosternal cartilages and the costal margin, collectively termed costal cartilage, are hyaline cartilage connecting ribs to the sternum and to adjacent ribs, respectively. Presence of intact costal cartilage is essential for elasticity of the chest wall. Anecdotally, costal cartilage injuries are underdiagnosed on trauma CT scan in patients with rib fractures. Our aim was to determine a baseline frequency of acute costal cartilage injury among patients presenting with rib fractures. Methods We performed a retrospective cohort study of injured adult patients admitted to Level I/II trauma centers with rib fractures from January 2020 to July 2024. CT images obtained at admission were manually reviewed by chest wall surgeons for presence of costal cartilage injury. Concordance with the original radiology report was obtained. Multivariable regression was used to analyze factors associated with costal cartilage injury and missed cartilage fractures. Results 1441 patients were identified; 197 (14%) had a costal cartilage fracture. A plurality of injuries included falls (n=667, 46%). Median ISS (Injury Severity Score) was 13 (IQR: 9 to 21), median Abbreviated Injury Scale thorax score was 3 (IQR: 3 to 3), and median number of fractured ribs was 3 (IQR: 3 to 7). 294 (21%) patients had radiographic flail segments, and 136 (9%) had sternal fractures. 172 (87%) patients had a costal cartilage fracture missed on initial trauma chest CT. On multivariable analysis, ISS (adjusted OR (aOR) 1.02 (95% CI 1.01 to 1.04), radiographic flail segment (aOR 1.6 (95% CI 1.10 to 2.31)) and presence of sternal fracture (aOR 1.85 (95% CI 1.19 to 2.89)) were associated with costal cartilage fractures. Only the total number of rib fractures was associated with a missed costal cartilage fracture on univariate analysis (OR 1.17 (95% CI 1.01 to 1.36)). Conclusions Costal cartilage injuries are common and frequently are not identified during interpretation of the initial trauma CT. A higher index of suspicion is warranted for costal cartilage fractures among patients with greater injury burden, radiographic flail segment, and sternal fractures. Level of evidence Level III.
In vivo detectability of tau‐PET tracers in Alzheimer's disease
Cecile, Tissot, Rahmouni, Nesrine, Tsai, Hsin‐Yeh, Therriault, Joseph, Macedo, Arthur, Servaes, Stijn, Stevenson, J. K. M. ller, Ziontz, Jacob , Liu, Peiwei, Gordon, Brian A., Pascual, Belen, Lowe, Val J. , Soleimani‐Meigooni, David, Oh, Hwamee, Klunk, William E, Rosa‐Neto, Pedro, Jagust, William J., Pascoal, Tharick A, Baker, Suzanne L. , Tissot, Cécile , Rahmouni, Nesrine , Therriault, Joseph , Macedo, Arthur C. , Servaes, Stijn , Stevenson, Jenna , Lussier, Firoza Zubeida , Trudel, Lydia , Gordon, Brian A. , Pascual, Belén , Soleimani‐Meigooni, David N. , Oh, Hwamee , Klunk, William E. , Rosa-Neto, Pedro , Jagust, William J. , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106041 Get It

Abstract Background Tau‐PET tracers are essential for visualizing pathology in Alzheimer's (AD). High detectability to tau is crucial for early detection and monitoring of tau deposition. This study compares the noise to dynamic range ratio (NRR) of [ 18 F]FTP, [ 18 F]MK6240, [ 18 F]PI2620, and [ 18 F]RO948, cross‐sectionally and longitudinally. Methods 460 individuals from the HEAD study (23 cognitively unimpaired (CU) young, 249 CU old and 188 cognitively impaired) underwent [ 18 F]FTP and [ 18 F]MK6240 tau‐PET scans; 94 additionally received [ 18 F]PI2620 and [ 18 F]RO948. A subset of 28 individuals (15 CU and 13 CI) underwent [ 18 F]FTP and [ 18 F]MK6240 follow‐up scans (1.5 ± 0.1 years later). Annual change was measured as [(followup‐baseline)/time between scans]. Noise was calculated as the standard deviation (SD) of CU Aβ‐ participants aged ≤65 (SD CUAβ‐≤65 ). The dynamic range was calculated as the SD across all subjects (SD range ). A lower the NRR (=SD CUAβ‐≤65 /SD range ) indicates more detectability. Analyses were performed at both region‐of‐interest and voxel‐wise levels. Results Across the whole cohort, [ 18 F]MK6240 exhibited lower NRR than [ 18 F]FTP in all regions. Voxel‐wise, differences were most pronounced in the frontal medial temporal regions (Figure 1). Within the four‐tracers subset, [ 18 F]PI2620 and [ 18 F]FTP showed the highest NRR in Braak II, followed by [ 18 F]RO948 and [ 18 F]MK6240. In Braak IV‐VI, [ 18 F]MK6240 consistently demonstrated the lowest values, followed by [ 18 F]PI2620, [ 18 F]FTP and [ 18 F]RO948. Similarly, in metatemporal‐ROI and Braak III, [ 18 F]MK6240 remained the lowest, however followed by [ 18 F]FTP, [ 18 F]PI2620 and [ 18 F]RO948 (Figure 2). Lower [ 18 F]MK6240 NRR was due to larger SD range , while [ 18 F]FTP's lower values stemmed from smaller SD CUAβ‐≤65 . Conversely, high [ 18 F]PI2620 and [ 18 F]RO948 values are driven by larger SD CUAβ‐≤65 . Longitudinal analyses further confirmed that [ 18 F]MK6240 exhibited the lowest NRR across the entire brain, including AD‐related regions, with voxel‐wise differences mainly in the temporal and parietal lobes. Conclusion Tau‐PET tracers exhibit significant variability in detectability. [ 18 F]MK6240 consistently demonstrated lower NRR, implying better detectability across all regions, cross‐sectionally and longitudinally. Despite differences in NRR, [ 18 F]FTP, [ 18 F]RO948 and [ 18 F]PI2620 followed similar pattern. These results provide insights into the differential tracer detectability, helping guide their optimal use in detecting and tracking tau pathology. Ongoing follow‐up scans will further clarify longitudinal tracer detectability and its implications for tau progression in AD.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Asken, Breton M., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N., Carrillo, Maria C., Casaletto, Kaitlin B, Cash, David M, Chang, Hsin‐I., Chao, Yishu , Chételat, Gael, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hanseeuw, Bernard J, Hansson, Oskar H., Harrison, Theresa, Huang, Qi, Huang, Shu‐Hua , Ishii, K, Ishii, Kenji, Jagust, William J., Katou, Rikio, Koeppe, Robert A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J, Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis, Rowe, Christopher C., Salvadó, Gemma, Schott, Jonathan M, Schwartz, Daniel, Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz , Silbert, Lisa C, Smith, Ruben, Sokolowski, Andrzej, Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, D., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Vemuri, Prashanthi, Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Joie, Renaud La, Consortia, AMYPAD and LEADS, Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chia‐Hsuin , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kenji, Jagust, William J. , Koeppe, Robert A. , Kramer, Joel H. , Landau, Susan , Landeau, Brigitte , Lee, Sangwon, Lopresti, Brian J. , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , O’Bryant, Sid E. , Pappas, Ioannis , Peretti, Débora Elisa , Quenon, Lisa , Rowe, Christopher C., Salvadó, Gemma , Schott, Jonathan M. , Schwartz, Daniel L., Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villain, Nicolas , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107124 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen's kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure 1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure 1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure 2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure 2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.